Microcap Ledger Oragenics Inc $OGEN
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- NYSE American
- Sector
- Pharmaceutical Preparations
- Headquarters
- Lakewood Ranch, FL
- Fiscal year end
- December 31
- Shares outstanding
- 4,511,957 [10-Q 2026-08-13]
What the company doesAI summary of filing
Oragenics Inc is a development-stage biopharmaceutical company focused on researching and developing nasal delivery pharmaceutical therapies for neurological conditions and infectious diseases. The company's lead product candidate is ONP-002, a synthetic neurosteroid in powder form delivered via a breath-powered intranasal device, currently being developed to treat mild traumatic brain injury (concussion). ONP-002 has completed preclinical animal studies and a Phase 1 clinical trial in healthy human subjects, with Phase 2a trials anticipated to start in the first quarter of 2026; the company is pre-revenue and has incurred significant operating losses since inception. If approved by regulatory authorities, Oragenics intends to commercialize ONP-002 through distribution agreements with industry partners or qualified distributors in the U.S. and internationally. [10-K 2026-03-16]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | — | −$4.73M | −$4.39M | $3.86M | [10-Q 2026-08-13] |
| FY ended Dec 2025 | — | −$984.25M | −$9.25M | $4.40M | [DEF 14A 2026-05-20] |
| FY ended Dec 2024 | — | −$1.06B | −$8.60M | $864.8K | [DEF 14A 2026-05-20] |
- Quarterly cash burn
- −$2.19M
- Cash runway Estimate
- ~5.3 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-11-13 | 12,212,680 | [10-Q 2024-11-13] |
| 2025-03-10 | 21,475,289 | [10-K 2025-03-14] |
| 2025-05-09 | 21,475,289 | [10-Q 2025-05-09] |
| 2025-08-07 | 4,127,173 | [10-Q 2025-08-08] |
| 2025-11-06 | 4,168,223 | [10-Q 2025-11-07] |
| 2026-03-13 | 4,336,029 | [10-K 2026-03-16] |
| 2026-05-07 | 4,511,957 | [10-Q 2026-05-08] |
| 2026-08-12 | 4,511,957 | [10-Q 2026-08-13] |
- Shelf registration
- S-3 filed 2026-01-22; declared effective 2026-03-20 [S-3 2026-01-22]
Listing status
Current status: 2 Form 8-K Item 3.01 filing(s) in the last 24 months, most recent 2026-08-28. Item 3.01 covers delisting notices, failures to meet a listing rule and listing transfers; read the filing for which one.
| Date | Event | Details | Deadline | Filing |
|---|---|---|---|---|
| 2026-08-28 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2026-08-28] |
| 2025-10-21 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2025-10-21] |
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2025-12-12 | Telling Fred | sell | 210 | $0.94 | [4 2025-12-15] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-09-16 | 8-K | Regulation FD disclosure; Other events |
| 2026-08-28 | 8-K | Listing notice or transfer; Other events |
| 2026-08-13 | 10-Q | Quarterly report |
| 2026-07-06 | 8-K | Material agreement entered; Director or officer change; Shareholder vote results |
| 2026-05-20 | DEF 14A | Proxy statement |
| 2026-05-19 | 8-K | Regulation FD disclosure; Other events |
| 2026-05-08 | PRE 14A | Proxy statement |
| 2026-05-08 | 10-Q | Quarterly report |
| 2026-05-07 | 8-K | Other events |
| 2026-04-13 | 8-K | Other events |
| 2026-03-19 | S-3/A | Registration statement |
| 2026-03-16 | 10-K | Annual report |
Alerts for $OGEN
Email me when Oragenics Inc files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.